MA47786A - Méthodes et compositions se rapportant à des immunoconjugués igg3 ciblant le facteur tissulaire - Google Patents

Méthodes et compositions se rapportant à des immunoconjugués igg3 ciblant le facteur tissulaire

Info

Publication number
MA47786A
MA47786A MA047786A MA47786A MA47786A MA 47786 A MA47786 A MA 47786A MA 047786 A MA047786 A MA 047786A MA 47786 A MA47786 A MA 47786A MA 47786 A MA47786 A MA 47786A
Authority
MA
Morocco
Prior art keywords
igg3
methods
tissue factor
compositions relating
targeting tissue
Prior art date
Application number
MA047786A
Other languages
English (en)
French (fr)
Inventor
Zhiwei Hu
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of MA47786A publication Critical patent/MA47786A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA047786A 2017-03-14 2018-03-14 Méthodes et compositions se rapportant à des immunoconjugués igg3 ciblant le facteur tissulaire MA47786A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471045P 2017-03-14 2017-03-14
US201762576278P 2017-10-24 2017-10-24
US201862623269P 2018-01-29 2018-01-29

Publications (1)

Publication Number Publication Date
MA47786A true MA47786A (fr) 2020-01-22

Family

ID=63523847

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047786A MA47786A (fr) 2017-03-14 2018-03-14 Méthodes et compositions se rapportant à des immunoconjugués igg3 ciblant le facteur tissulaire

Country Status (8)

Country Link
US (2) US11872194B2 (https=)
EP (1) EP3595707A4 (https=)
JP (1) JP7155144B2 (https=)
CN (1) CN110520152A (https=)
AU (1) AU2018235945A1 (https=)
CA (1) CA3056396A1 (https=)
MA (1) MA47786A (https=)
WO (1) WO2018170134A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3687555A4 (en) * 2017-09-27 2021-07-21 Ohio State Innovation Foundation CAR-NK CELL THERAPY AND CAR-T TISSUE FACTOR TARGETING
WO2022106648A1 (en) 2020-11-20 2022-05-27 Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Inhibitors of the tissue factor-protease activated receptor 2 (tf-par2) signaling pathway for use in the treatment or prevention of heart failure (hf) and associated or resulting diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5095030A (en) 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US4883790A (en) 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US5190966A (en) 1988-07-06 1993-03-02 Health Research, Inc. Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
US4968715A (en) 1988-07-06 1990-11-06 Health Research, Inc. Use of purified hematoporphyrin trimers in photodynamic therapy
US5093349A (en) 1988-07-20 1992-03-03 Health Research Inc. Photosensitizing agents
US5198460A (en) 1988-07-20 1993-03-30 Health Research Inc. Pyropheophorbides and their use in photodynamic therapy
US5002962A (en) 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5173504A (en) 1989-04-21 1992-12-22 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5171741A (en) 1989-04-21 1992-12-15 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5079262A (en) 1989-07-28 1992-01-07 Queen's University At Kingston Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
US5166197A (en) 1990-07-17 1992-11-24 Kenney Malcolm E Phthalocyanine photosensitizers for photodynamic therapy
US5244914A (en) 1992-04-27 1993-09-14 American Cyanamid Company Stable porfimer sodium compositions and methods for their manufacture
US6924359B1 (en) * 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
DK1198479T3 (da) 1999-07-01 2008-10-13 Univ Yale Neovaskulamålrettet immunkonjugat
US6443976B1 (en) 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
CA2408323C (en) 2000-05-08 2012-06-12 The University Of British Columbia Drug delivery systems for photodynamic therapy
US20040110929A1 (en) * 2002-07-12 2004-06-10 Bjorn Soren E. TF binding compound
PT1624891E (pt) * 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2006020979A2 (en) * 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
SG10201505217WA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
CN104774269B (zh) * 2013-08-16 2016-02-24 安源生物科技(上海)有限公司 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
BR112018001148A2 (pt) * 2015-08-06 2018-09-11 Glycotope Gmbh heterômeros compreendendo proteínas de fusão com domínios de anticorpos
EP3442554A4 (en) * 2016-04-14 2019-12-04 Iconic Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATING DISEASES RELATED TO NEOVASCULARIZATION

Also Published As

Publication number Publication date
AU2018235945A1 (en) 2019-10-17
JP2020511140A (ja) 2020-04-16
US20200085922A1 (en) 2020-03-19
JP7155144B2 (ja) 2022-10-18
EP3595707A1 (en) 2020-01-22
US11872194B2 (en) 2024-01-16
WO2018170134A1 (en) 2018-09-20
CN110520152A (zh) 2019-11-29
EP3595707A4 (en) 2021-01-13
CA3056396A1 (en) 2018-09-20
US20240123042A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
EP3673055A4 (en) RNA TARGETING METHODS AND COMPOSITIONS
EP3355954A4 (en) RELEASE PROCEDURE AND COMPOSITIONS
EP3554558A4 (en) HSP90 TARGETING CONJUGATES AND FORMULATIONS OF THE LATEST
EP3501548A4 (en) ANTIBODY-ACTIVE SUBSTANCE CONJUGATE TISSUE FABRIC FACTOR
EP3615040C0 (en) HAIR TREATMENT COMPOSITIONS
SI3585803T1 (sl) Formulacije konjugiranega pnevmokoknega cepiva
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
EP3668541A4 (en) FORMULATIONS FOR PNEUMOCOCCAL CONJUGATE VACCINE
EP3723811A4 (en) TARGETING HSP90 CONJUGATES AND FORMULATIONS OF THE LATTER
EP3737400A4 (en) COMPOSITIONS AND PROCEDURES FOR CLEC12A EXPRESSING CARCINOMA
DK3265084T3 (da) Farmaceutiske formuleringer af Bruton's tyrosinkinase-hæmmer
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
MA47611A (fr) Compositionset méthodes de transduction tumorale
SI3346995T1 (sl) Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
EP3773670A4 (en) Hsp90-targeting conjugates and formulations thereof
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
EP3436467A4 (en) INNOVATIVE COMPOSITIONS AND THERAPEUTIC PROCEDURES
PL3655013T3 (pl) Ukierunkowanie na synaptogirynę-3 w leczeniu tauopatii
IL283787A (en) Herboxidiene antibody-drug conjugates and methods of use
EP3675860A4 (en) SUBSTITUTED PYRIMIDINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC PROCEDURES THEREFORE
EP3687491A4 (en) HAIR CARE COMPOSITIONS AND METHODS
DK3697418T3 (da) Forbedrede formuleringer af bromocriptin
EP3429559A4 (en) WELLBEING COMPOSITIONS WITH SODIUM PHENYL BUTYRATE AND USES THEREOF
DK3895736T5 (da) Antistof-lægemiddelkonjugater rettet mod uPARAP
EP4031520A4 (en) IMAGING AND THERAPEUTIC COMPOSITIONS